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OBJECTIVE— The purpose of this study was to examine prospectively whether renal hy-
perfiltration is associated with the development of microalbuminuria in patients with type 1
diabetes, after taking into account known risk factors.
RESEARCHDESIGNANDMETHODS— The study group comprised 426 participants
with normoalbuminuria from the First Joslin Kidney Study, followed for 15 years. Glomerular
filtration rate was estimated by serum cystatin C, and hyperfiltration was defined as exceeding
the 97.5th percentile of the sex-specific distribution of a similarly aged, nondiabetic population
(134 and 149 ml/min per 1.73 m2 for men and women, respectively). The outcome was time to
microalbuminuria development (multiple albumin excretion rate 30 g/min). Hazard ratios
(HRs) for microalbuminuria were calculated at 5, 10, and 15 years.
RESULTS— Renal hyperfiltration was present in 24% of the study group and did not increase
the risk of developing microalbuminuria. The unadjusted HR for microalbuminuria comparing
those with and without hyperfiltration at baseline was 0.8 (95% CI 0.4–1.7) during the first 5
years, 1.0 (0.6–1.7) during the first 10 years, and 0.8 (0.5–1.4) during 15 years of follow-up. The
model adjusted for baseline known risk factors including A1C, age at diagnosis of diabetes,
diabetes duration, and cigarette smoking resulted in similar HRs. In addition, incorporating
changes in hyperfiltration status during follow-up had minimal impact on the HRs for mi-
croalbuminuria.
CONCLUSIONS— Renal hyperfiltration does not have an impact on the development of
microalbuminuria in type 1 diabetes during 5, 10, or 15 years of follow-up.
Diabetes Care 32:889–893, 2009
The glomerular filtration rate (GFR),the volume of water filtered out ofthe plasma per unit of time, is indic-
ative of overall kidney function. However,
measuring GFR with the gold standard
technique is an intensive process and dif-
ficult for both the operator and the par-
ticipant. Thus, it has not been practical to
determine GFR in large epidemiological
studies. Instead, serum creatinine has
been widely used to estimate low levels of
GFR when loss of kidney function has al-
ready occurred. However, serum creati-
nine is not sensitive enough to detect
changes when renal function is normal or
abnormally elevated (1). A laboratory test
to estimate GFR based on serum cystatin
C levels has been developed recently.
Cystatin C assays are easy to perform
and have been shown to yield accurate
estimates even in the normal or elevated
ranges of filtration (2,3). This develop-
ment has created a new opportunity for
studying early diabetic renal function
abnormalities in large epidemiological
studies.
Hyperfiltration has been suggested as
a risk factor for the development of mi-
croalbuminuria (4). The increase in pres-
sure and flow may lead to functional and
structural changes in the kidney (5,6). In
several small studies, hyperfiltration was
associated with the development of mi-
croalbuminuria in type 1 diabetes, but re-
sults have been inconsistent. Some
studies were conducted in children be-
ginning at diagnosis or early in the course
of diabetes, and usually a few events of
microalbuminuria were observed (7–11).
Yip et al. (12) found no association be-
tween hyperfiltration and microalbumin-
uria in a 10-year prospective case control
study of 25 adult pairs who had diabetes
duration between 1 and 19 years. None of
these studies adequately addressed con-
founders. Little subsequent research in
large cohorts has been conducted on the
role of hyperfiltration, primarily due to
difficulties in determining GFR.
Scott et al. (13) studied microalbu-
minuria onset in the First Joslin Study on
the Natural History of Microalbuminuria
(First Joslin Kidney Study) during the first
4 years of follow-up (13). They found
that younger age at diabetes diagnosis,
longer diabetes duration, poorer glyce-
mic control, and cigarette smoking were
associated with the development of mi-
croalbuminuria. Serum cystatin C mea-
surements (to estimate GFR) were not
available at the time of that work. The
current project builds upon this prior
study by examining whether hyperfil-
tration, as measured by cystatin C, is
associated with the development of mi-
croalbuminuria during 15 years of fol-
low-up, after taking into account
known risk factors.
RESEARCH DESIGN AND
METHODS— The study group is de-
rived from the cohort of the First Joslin
Kidney Study. Enrollment was as follows.
From January 1991 to April 1992, every
other Joslin Clinic patient with type 1 di-
abetes aged 15–44 years who resided in
Massachusetts had his or her urine exam-
ined for microalbuminuria using an albu-
min-to-creatinine ratio (ACR). Based on
the initial screening and additional mea-
surements obtained over a 2-year baseline
interval, patients (n  1,602) were cate-
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gorized as having normoalbuminuria
(n  1,080), microalbuminuria (n 
312), or proteinuria (n 210). Men with
a median ACR17 mg/g or women with
a median ACR 25 mg/g were classified
as having normoalbuminuria, and men
with median ACR between 17 and 250
mg/g and women with median ACR be-
tween 25 and 355 mg/g were classified as
having microalbuminuria. Patients with
proteinuria were not followed for assess-
ments of albumin excretion rate (AER).
All participants with microalbuminuria
and a 50% sample of participants with
normoalbuminuria were invited to partic-
ipate in an entry examination during the
first 2 years of the study. The participants
with normoalbuminuria who still had
stored blood samples for measuring cys-
tatin C were the focus of the current
investigation.
Entry examination and
measurements of characteristics and
exposures
At the entry examination, a trained study
recruiter administered a questionnaire to
obtain medical and diabetes history, col-
lected samples of blood and urine, and
measured seated blood pressures twice,
separated by a 5-min rest. Chart review
supplemented the questionnaire informa-
tion as needed.
Electronic medical record informa-
tion captured clinical characteristics
such as repeated measures of A1C and
ACR. Details of these assays have been
published previously (14). The equa-
t ion for the convers ion of ACR
to AER was log10(AER)  0.44 
(0.85)log10(ACR)  (0.13)sex, where
sex  1 for women and 0 for men (14).
Baseline A1C was the mean of all A1C
measurements over the year before entry
examination including A1C measured at
the examination. Baseline exposures and
characteristics measured for study-
specific reasons (such as cystatin C) or
related to calendar time (such as age and
duration of diabetes) were measurements
from the date of entry examination.
Serum cystatin C has been shown to
estimate GFR well in diabetic populations
with normal or elevated renal function
(2,3,15). The equation to estimate GFR
from cystatin C was developed by Ma-
cisaac et al. (3) (cystatin C-GFR  [86.7/
cystatin C]  4.2). All serum samples
were stored at85°C until the day of as-
say. Samples were thawed, vortexed for
5 s, and microcentrifuged at 13,200 rpm
for 10 min. Samples were then analyzed
for cystatin C concentration (Dade Be-
hring, Newark, DE) on a BN ProSpec Sys-
tem nephelometer (Dade Behring). The
reported reference interval for cystatin C
is 0.53–0.95 mg/l for young, healthy in-
dividuals. Factory-provided controls
were measured on the day of each run for
quality control.
We estimated cystatin C-GFR in
healthy nondiabetic individuals aged
18–44 years. They were the nondiabetic
relatives examined for our family-based
study of the genetics of diabetic nephrop-
athy in type 2 diabetes (16). Their serum
cystatin C concentrations were deter-
mined in the same laboratory and by the
same method as those for the current
study. In these nondiabetic individuals,
the distribution of cystatin C-GFR was
higher for women than for men (Fig. 1).
We defined hyperfiltration as a cystatin
C-GFR exceeding the sex-specific 97.5th
percentile in nondiabetic subjects:149
and 134 ml/min per 1.73 m2 for wo-
men and men, respectively. In previous
studies authors used similar definitions
(125–140 ml/min per 1.73 m2), but the
definitions were not sex-specific (6–8).
Follow-up of eligible study group
Patients were followed for the develop-
ment of microalbuminuria over 15 years
through routine clinic appointments,
home visits by patient recruiters, and
mailed urine kits. Of the 502 patients
with a study examination, 473 partici-
pants qualified by having samples re-
maining for the measurement of cystatin
C-GFR. We excluded participants who
developed microalbuminuria before the
first examination and those with1 year
AER follow-up after examination (n 
17). Also excluded were 30 participants
who did not have A1C measurements
Figure 1—A: Distribution of cystatinC-GFRmeasurements at baseline inmenwith (F,n210) and
without (f, n  127) diabetes of similar age (18–44 years). B: Distribution of cystatin C-GFR
measurements at baseline in women with (F, n 216) and without (f, n 136) diabetes of similar
age (18–44 years). Measurements of serum cystatin C concentrations in diabetic subjects and nondi-
abetic subjectswere performed in the same laboratory and according to the samemethod, and the same
formula was used to estimate cystatin C-GFR (see RESEARCH DESIGN AND METHODS).
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within 1 year before the cystatin C-GFR
measurement and those who did not have
information on smoking status. Thus,
426 participants remained eligible for this
study.
Outcome: time to onset of
microalbuminuria
The outcome was time to development of
microalbuminuria. The onset of mi-
croalbuminuria occurred when two con-
secutive AER measurements reached the
microalbuminuria range (AER 30
g/min). The date of the first AER of the
pair was the date of the onset.
Statistical methods
All statistical analyses were conducted in
SAS (version 9.1; SAS Institute, Cary,
NC). Descriptive analyses (mean SD for
continuous variables and percentage and
counts for categorical variables) com-
pared clinical characteristics among those
with and without hyperfiltration during
baseline.
The hazard ratio (HR) of developing
microalbuminuria during 5, 10, and 15
years of follow-up and the corresponding
95% CIs were calculated using Cox pro-
portional hazards modeling (PROC
PHREG). Next, adjusted HRs were calcu-
lated, comparing participants who were
and were not hyperfiltering at baseline.
The potential confounders (baseline A1C,
age at diabetes diagnosis, diabetes dura-
tion, and cigarette smoking status) were
entered into the multivariate model. To
assess effect measure modification, we
stratified on sex, baseline A1C, age at di-
abetes diagnosis, and diabetes duration.
Changes in the hyperfiltration status
of patients with multiple cystatin C-GFR
measures over time were determined. To
be eligible for this analysis, patients had
at least two determinations at least 2
years apart. The median was three de-
terminations and median follow-up of
cystatin C-GFR was 9 years. Over time,
hyperfiltration could have been consis-
tently present, consistently absent, or
inconsistent. These results were incor-
porated into an analysis that allowed
hyperfiltration status to vary over time.
Last, as in the analysis of baseline hy-
perfiltration status, unadjusted and ad-
justed HRs for microalbuminuria were
calculated during 5, 10, and 15 years of
follow-up.
RESULTS— Characteristics of study
participants with and without renal hy-
perfiltration at baseline are displayed in
Table 1. Renal hyperfiltration was defined
as a cystatin C-GFR exceeding 134 and
149 ml/min per 1.73 m2 for men and
women, respectively, the sex-specific
97.5th percentiles in nondiabetic individ-
uals (Fig. 1). There were 24% of patients
with renal hyperfiltration in the study
group. Those with hyperfiltration were
older, were more likely to be female, and
had shorter diabetes duration, later age of
onset of diabetes, and slightly higher A1C
levels. Systolic and diastolic blood pres-
sure, BMI, and percentage of current
smokers were similar among those with
and without hyperfiltration. Microalbu-
minuria developed in 23% (74 of 322) of
participants without and 19% (20 of 104)
of those with hyperfiltration at baseline.
HRs for developing microalbumin-
uria comparing participants with and
without hyperfiltration at baseline are
shown in Table 2. Hyperfiltration did not
increase the rate of developing microalbu-
minuria. The unadjusted HR was 0.8
(95% CI 0.4–1.7) during the first 5 years,
1.0 (0.6–1.7) during the first 10 years,
and 0.8 (0.5–1.4) during 15 years of fol-
low-up. In a model adjusting for known
risk factors for microalbuminuria (A1C,
age at diabetes diagnosis, diabetes dura-
tion, and current cigarette smoking), the
HRs were little changed: 0.8 (0.4–1.7)
during the first 5 years, 1.0 (0.5–1.7) dur-
ing the first 10 years, and 0.9 (0.6–1.4)
during 15 years of follow-up. There was
also no effect measure modification due to
sex, baseline A1C, age at diabetes diagno-
sis, and diabetes duration. Results were
identical to those in Table 2, when we
performed a sensitivity analysis using
lower (95th percentile) or higher (99th
percentile) cutoffs for renal hyperfiltra-
tion (data not shown).
There were 243 participants with
multiple cystatin C-GFR measures over
follow-up. Hyperfiltration was absent
throughout follow-up (median 11 years)
in 69% (167 of 243). Hyperfiltration was
consistently present in 4% (9 of 243);
however, they had shorter follow-up than
those whose hyperfiltration status
changed. Hyperfiltration status changed
in 28% (67 of 243). In the majority of
these individuals, baseline hyperfiltration
resolved during follow-up (37 of 67). In a
few instances, baseline hyperfiltration re-
solved only to return (n  9). In the re-
mainder, hyperfiltration developed
during follow-up and remained (n  13)
or resolved to normal (n 8). Similar to
the consistently hyperfiltering group,
the group with hyperfiltering that de-
veloped during follow-up and remained
had shorter follow-up than other
groups. This suggests that if follow-up
were longer, these participants may
have returned to normal filtration lev-
els, albeit this was a small proportion of
the total group with follow-up cystatin
C-GFR (19 of 243).
Incorporating changes in hyperfiltra-
tion status over follow-up (time-varying
analysis) had minimal impact on the HR.
The unadjusted HR for microalbuminuria
comparing those with and without hyper-
filtration at baseline was 0.6 (95% CI 0.3–
1.4) during the first 5 years, 1.0 (0.6–1.7)
during the first 10 years, and 1.0 (0.6–
1.7) during 15 years of follow-up. Similar
to the analysis of baseline hyperfiltration,
there was minimal confounding due to
the other risk factors. The adjusted HR
during 5, 10, and 15 years of follow-up
was 0.7 (0.3–1.5), 1.0 (0.6–1.8), and 1.1
(0.7–1.8), respectively.
Table 1—Selected baseline characteristics of participants according to baseline renal
hyperfiltration status
No hyperfiltration Hyperfiltration
n 322 104
Women (%) 48 61
Age (years) 29  8 31  7
Diabetes duration (years) 14  8 12  7
Age of diabetes diagnosis (years) 15  8 19  8
A1C (%) 8.1  1.3 8.6  1.7
Systolic blood pressure (mmHg) 119  13 117  14
Diastolic blood pressure (mmHg) 71  8 72  8
Current smoking (%) 17 18
BMI (kg/m2) 24.3  3.0 23.1  2.6
Cystatin C-GFR (ml/min per 1.73 m2) 122  13 155  13
Developed microalbuminuria (%)* 23 19
Data are means  SD or %. *Developed confirmed microalbuminuria during 15 year follow-up.
Ficociello and Associates
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CONCLUSIONS— In our 15-year
follow-up of AER in a cohort of young
adults with type 1 diabetes, neither the
presence of hyperfiltration at baseline nor
its development subsequently was a risk
factor for the development of microalbu-
minuria within 5, 10, or 15 years. There
was very little confounding by A1C, age at
diabetes diagnosis, diabetes duration, and
current cigarette smoking in the relation
between hyperfiltration and microalbu-
minuria development. There was also no
effect measure modification on the rela-
tion between hyperfiltration and mi-
croalbuminuria due to sex, baseline A1C,
age at diabetes diagnosis, and diabetes
duration.
In the subset of the cohort with mul-
tiple measurements of cystatin C-GFR
during follow-up, we characterized the
patterns of change in hyperfiltration sta-
tus. It did not change in the majority of
individuals. Hyperfiltration was never
present in 66% and always present in 4%.
In the remaining 30% in whom the status
changed, the change was resolution of hy-
perfiltration in the majority and develop-
ment of hyperfiltration in a small
minority.
Most data on the biological mecha-
nisms underlying the impact of hyperfil-
tration on the kidney come from animal
models (17). In those models, hyperfiltra-
tion increases glomerular pressure and
flow, which initiate destructive processes
in the kidney (5,6). However, hyperfiltra-
tion is benign in some human conditions
other than diabetes, so hyperfiltration
cannot be the problem by itself (18). Un-
der experimental conditions, induction of
hyperglycemia in humans with diabetes
increases the GFR in those with hyperfil-
tration but not in those with normal GFR
or in individuals without diabetes (19). In
our study, hyperglycemia predicted the
onset of microalbuminuria, but hyperfil-
tration did not, so the effect of glycemic
control is not through an effect on GFR.
Our findings differ from the results of
several studies, but the disagreements
may be due to methodological limitations
in those studies. For instance, in the study
by Chiarelli et al. (7), hyperfiltration pre-
dicted microalbuminuria over a 10-year
follow-up in a prospective case-control
study of children and young adults aged
9 –19 years. However, with only eight
cases of microalbuminuria divided be-
tween 23 individuals with hyperfiltration
and 23 without, their result has large sta-
tistical uncertainty. Moreover, the analy-
sis did not control for confounding by
A1C. Amin et al. (8) tested the hyperfil-
tration and microalbuminuria hypothesis
in a 5-year follow-up study of 273 chil-
dren with diabetes duration of 5 years.
Microalbuminuria developed in 30 chil-
dren. After controlling for A1C, the esti-
mated HR of 1.02 per unit of GFR was
statistically significant. The clinical mean-
ingfulness, however, of such a small effect
is questionable.
On the other hand, our findings are
consistent with a number of studies. In
the late 1980s, Lervang et al. (20) studied
29 patients with type 1 diabetes who had
been studied 18 years previously when
diabetes duration averaged 2 years (range
0–9). The AER did not differ according to
hyperfiltration status at baseline. They
suggested that the disagreement with
other study findings might have been due
to their population’s older age at onset of
diabetes (age 19 on average) (21,22).
Steinke et al. (11) did not find compelling
evidence that hyperfiltration predicted
microalbuminuria and suggested that dif-
ferences among studies may be due to
variable definitions of hyperfiltration and
AER progression and the inclusion of pa-
tients with very short durations of diabe-
tes. Levine (17) hypothesized that the
duration of hyperfiltration, which is not
usually taken into consideration, may be
an important factor in kidney damage.
One 5-year prospective case-control
study of adults with type 1 diabetes and
without proteinuria or hypertension
found no difference in AER according to
hyperfiltration status at baseline (23).
However, in this study the rate of renal
function decline was faster in those with
hyperfiltration than in those without. In a
study of the same patients at 10 years of
follow-up, the rate of decline continued to
differ according to hyperfiltration status
at baseline. However, the absolute GFR
remained higher in the hyperfiltration
group (12).
The First Joslin Kidney Study has
many strengths, including a large, well-
characterized cohort followed prospec-
tively over 15 years. The availability of a
detailed entry questionnaire and repeated
visits that generated laboratory data and
stored specimens allowed the examina-
tion of novel definitions of exposures and
outcomes. Moreover, frequent AER mea-
surements yielded more reliable determi-
nations of renal status than studies based
on single measurements, and the sample
size enabled us to control for confounders
and assess effect measure modification.
One limitation of the current study,
however, is that an individual with hyper-
filtration occurring and resolving before
entry into the study was misclassified.
Similarly, we were unable to assess the
effect of hyperfiltration occurring and re-
solving very soon after diabetes onset due
to the small number of individuals stud-
ied with5 years duration of diabetes. It
is possible that renal hyperfiltration has a
more immediate impact on the develop-
ment of microalbuminuria, and studies
started during childhood have captured
this information, but follow-up was short
so outcomes were few.
In summary, this study provides evi-
dence that hyperfiltration is not a risk factor
for the development of microalbuminuria
in type 1 diabetes. There was little change in
the HR at 5, 10, or 15 years when known
risk factors and potential confounders
Table 2—Unadjusted and adjusted HRs of developing microalbuminuria comparing individ-
uals with and without renal hyperfiltration at baseline
Events of
microalbuminuria
Total
person-years
HR (95% CI)
Unadjusted Adjusted
5-year HR
No hyperfiltration 35 1,500 1 (Ref) 1 (Ref)
Hyperfiltration 9 486 0.8 (0.4–1.7) 0.8 (0.4–1.7)
10-year HR
No hyperfiltration 53 2,744 1 (Ref) 1 (Ref)
Hyperfiltration 17 888 1.0 (0.6–1.7) 1.0 (0.5–1.7)
15-year HR
No hyperfiltration 74 3,574 1 (Ref) 1 (Ref)
Hyperfiltration 20 1,145 0.8 (0.5–1.4) 0.9 (0.6–1.4)
Hyperfiltration is defined as exceeding the 97.5th percentile of cystatin C-GFR in a nondiabetic, similarly
aged population. For women this cutoff was 149 ml/min per 1.73 m2 and for men 134 ml/min per 1.73 m2.
*Adjusted by baseline mean A1C, age at diabetes diagnosis, diabetes duration, and current cigarette smok-
ing. Ref, referent.
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were accounted for, and there was no ef-
fect measure modification by sex, baseline
A1C, age at diabetes diagnosis, and diabe-
tes duration.
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